Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLB Ltd
SLB
|
+$461M |
| 2 |
Qualcomm
QCOM
|
+$450M |
| 3 |
Marriott International
MAR
|
+$341M |
| 4 |
TIF
Tiffany & Co.
TIF
|
+$283M |
| 5 |
NRG Energy
NRG
|
+$207M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$962M |
| 2 |
ESRX
Express Scripts Holding Company
ESRX
|
+$551M |
| 3 |
WFM
Whole Foods Market Inc
WFM
|
+$510M |
| 4 |
Goldman Sachs
GS
|
+$478M |
| 5 |
Estee Lauder
EL
|
+$329M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.96% |
| 2 | Consumer Discretionary | 14.17% |
| 3 | Communication Services | 11.56% |
| 4 | Technology | 11.12% |
| 5 | Energy | 10.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PSXP
451
DELISTED
PHILLIPS 66 PARTNERS LP
PSXP
| $15.2M | 0.01% |
200,975
+9,134
| +5% | +$548K |
|
452
Madrigal Pharmaceuticals
MDGL
$12.8B
| $15M | 0.01% |
104,855
-8,869
| -8% | -$1.3M |
|
|
VITC
453
DELISTED
VITACOST COM INC COM STK (DE)
VITC
| $14.9M | 0.01% |
2,374,492
+3,641
| +0.2% | +$23.7K |
|
|
ZU
454
DELISTED
ZULILY INC CLASS A COMMON STOCK
ZU
| $14.6M | 0.01% |
357,140
-99,509
| -22% | -$4M |
|
455
Puma Biotechnology
PBYI
$412M
| $14.2M | 0.01% |
214,547
-215,061
| -50% | -$15.3M |
|
|
ACOR
456
DELISTED
Acorda Therapeutics
ACOR
| $14.1M | 0.01% |
+3,496
| New | +$14.3M |
|
|
TFM
457
DELISTED
THE FRESH MARKET, INC COM STK
TFM
| $13.9M | 0.01% |
415,457
-134
| -0% | -$4.53K |
|
458
Douglas Emmett
DEI
$2.04B
| $13.9M | 0.01% |
491,050
-26,542
| -5% | -$739K |
|
459
Robert Half
RHI
$4.01B
| $13.6M | 0.01% |
+284,812
| New | +$12.8M |
|
|
CMRX
460
DELISTED
Chimerix, Inc.
CMRX
| $13.5M | 0.01% |
616,822
-44,465
| -7% | -$883K |
|
|
DSCI
461
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $13.3M | 0.01% |
1,147,940
-123,981
| -10% | -$1.27M |
|
|
MLU
462
DELISTED
METLIFE, INC. COM EQUITY UNIT
MLU
| $13.2M | 0.01% |
413,000
| – | – |
|
|
PFPT
463
DELISTED
Proofpoint, Inc.
PFPT
| $13.1M | 0.01% |
350,031
+38,029
| +12% | +$1.22M |
|
464
MPLX
MPLX
$59.6B
| $12.5M | 0.01% |
193,835
-7,334
| -4% | -$417K |
|
|
I.PRA
465
DELISTED
INTELSAT S A MANDATORY CONV JR NON VTG PFD SHS (LUX)
I.PRA
| $12.3M | 0.01% |
242,300
| – | – |
|
|
AVDL
466
DELISTED
Avadel Pharmaceuticals
AVDL
| $12.3M | 0.01% |
819,787
-680,213
| -45% | -$8.2M |
|
467
Marcus & Millichap
MMI
$1.18B
| $11.9M | 0.01% |
467,773
+21,266
| +5% | +$421K |
|
468
Asbury Automotive
ABG
$4.23B
| $11.9M | 0.01% |
172,727
-34,183
| -17% | -$2.11M |
|
|
FLXN
469
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $11.1M | 0.01% |
820,677
+90,878
| +12% | +$1.24M |
|
|
FCSC
470
DELISTED
Fibrocell Science Inc.
FCSC
| $11M | 0.01% |
184,151
-13,139
| -7% | -$733K |
|
471
Agios Pharmaceuticals
AGIO
$2.23B
| $10.9M | 0.01% |
237,239
-72,168
| -23% | -$2.94M |
|
472
PUT
BioMarin Pharmaceuticals
BMRN
$11.7B
| $10.8M | 0.01% |
172,800
-172,800
| -50% | -$10.4M |
|
473
Arrowhead Research
ARWR
$12.1B
| $10.7M | 0.01% |
746,366
-30,380
| -4% | -$398K |
|
474
PUT
Alnylam Pharmaceuticals
ALNY
$37.7B
| $10.5M | 0.01% |
166,300
| – | – |
|
475
Tractor Supply
TSCO
$16.7B
| $10.4M | 0.01% |
860,120
-3,538,790
| -80% | -$46.4M |
|
Similar funds
Jennison Associates's Q2 2014 Portfolio in Review
As of Q2 2014, Jennison Associates held 796 positions worth $109B, up 4.1% from $105B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Jennison Associates's Q2 2014 filing shows 64 new, 297 increased, 319 reduced and 90 closed positions. Its largest new stake was Qualcomm: 5,657,444 shares worth $448M. The largest sale was Allergan Inc, an estimated $962M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, down from 20% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q2 2014 buy was Qualcomm: 5,657,444 shares worth $448M.
- Jennison Associates added most to SLB Ltd in Q2 2014, an estimated $461M increase.
- Jennison Associates's biggest Q2 2014 reduction was Allergan Inc, cutting an estimated $962M.
- Jennison Associates fully exited Estee Lauder in Q2 2014, selling an estimated $329M.
- Jennison Associates's ten largest holdings make up 19% of its $109B portfolio in Q2 2014.
- Jennison Associates opened 64 new positions and closed 90 in Q2 2014.
- Jennison Associates's portfolio value rose 4.1% quarter-over-quarter to $109B.
Based on Jennison Associates's 13F filing for Q2 2014, filed 8 Aug 2014.